New tools for measuring what’s going on and for guiding treatment and entirely new approaches to treatment.
- We’ve started using a genetic screening tool that in about 1/3 of patients with treatment resistant depression, yields insights about the most effective treatment. Read more about the Genecept assay here.
- A recent article suggested that a common medical lab test (C reactive protein) may distinguish types of depression with different responses to different medications. For more read the article in the American Journal of Psychiatry.
- And we’ve been measuring brain function with the use of neuropsychological testing (CNS Vital Signs) to correlate changes in brain function with mood and medication changes.
- We have recently started using rapid Transcranial Magnetic Stimulation (TMS) a non-invasive, non-medication based treatment of depression with almost no long term adverse effects to treat patients with depression, with some early compelling results.
- Finally, there is compelling evidence that glutamate modulators – like ketamine – have profound and dramatic effects on depression, raising the potential of an entirely new class of medications.
For a long time it has seemed as though the treatment of depression from a neurobiological standpoint had stalled with more and more “me too” medications but nothing really new to help us provide more effective. That time seems to be passing.